Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626133 | 0.87 | PIK3CA (0.47) | PIK3CARIPK1CDK2PIK3CD | |
| SCHEMBL625127 | 0.86 | PIK3CA (0.48) | PIK3CARIPK1SYKCCNA2CDK2 | |
| SCHEMBL624984 | 0.84 | PIK3CA (0.48) | PIK3CARIPK1 | |
| SCHEMBL624921 | 0.82 | PIK3CA (0.49) | PIK3CARIPK1GPR119 | |
| SCHEMBL625280 | 0.82 | PIK3CA (0.49) | PIK3CA | |
| SCHEMBL625652 | 0.82 | PIK3CA (0.49) | PIK3CAPIK3CD | |
| SCHEMBL625862 | 0.80 | PIK3CA (0.47) | PIK3CAPIK3CD | |
| SCHEMBL625421 | 0.80 | PIK3CA (0.52) | PIK3CARIPK1GPR119 | |
| SCHEMBL626544 | 0.80 | ACKR3 (0.55) | PIK3CARIPK1 | |
| SCHEMBL622971 | 0.79 | ALDH1A1 (0.41) | CCNA2CDK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |